MNM implements project: PARPiNDx, a novel genomic based classifier for prediction of PARP inhibitor response in ovarian cancer.
The project has received funding from the Eurostars Joint Programme with co-funding from the European Union Horizon 2020 Research and Innovation Programme and The National Centre for Research and Development.
Project goal: The aim of the project is to create an AI-powered diagnostic tool - PARPiNDx, designed to improve ovarian cancer patient classification, increasing their chances for successful clinical outcomes. PARPiNDx utilizes the most advanced genomic sequencing technology, and an AI approach to select patients, who will respond to PARP inhibitors.
Total value: EURO 698,679.00
Financial support: EURO 271,557.10
Project number: 653
Eureka website: www.eurekanetwork.org
NCRD website: www.gov.pl/web/ncbr